Enanta Pharmaceuticals, Inc. (ENTA)

15,17 +1,26 (+9,06%) Alla chiusura: 04:00PM EDT

Enanta Pharmaceuticals, Inc.

500 Arsenal Street
Watertown, MA 02472
United States
617 607 0800
https://www.enanta.com

Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 145

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Dr. Jay R. Luly Ph.D.	President, CEO & Director	1,25M	2,03M	1956
Mr. Paul J. Mellett Jr.	Senior VP of Finance & Administration and CFO	666,84k	529,98k	1955
Dr. Yat Sun Or Ph.D.	Senior VP of Research & Development and Chief Scientific Officer	729,31k	424,85k	1952
Mr. Nathaniel S. Gardiner J.D.	Consultant	672,67k	49,14k	1954
Mr. Brendan Luu	Senior Vice President of Business Development	622,86k	N/D	1975
Ms. Jennifer Viera	Senior Director of Investor Relations & Corporate Communications	N/D	N/D	N/D
Mr. Matthew P. Kowalsky J.D.	Chief Legal Officer	N/D	N/D	1973
Ms. Tara Lynn Kieffer Ph.D.	Senior Vice President of New Product Strategy & Development	496,85k	N/D	1978
Dr. Scott T. Rottinghaus M.D.	Senior VP & Chief Medical Officer	616,73k	N/D	1974

Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. The company has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. Enanta Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Watertown, Massachusetts.

Governance aziendale

L'ISS Governance QualityScore di Enanta Pharmaceuticals, Inc. al 1 maggio 2024 è 6. I criteri di valutazione fondamentali sono revisione: 3; Consiglio di Amministrazione: 4; diritti degli azionisti: 8; retribuzione: 7.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.